International: +1-347-960-6455
Bromodomain and Extraterminal Domain (BET) Inhibitors Pipeline to Witness Significant Growth Due to High Potential of the Market in the Coming Years

According to a new research report Bromodomain and Extraterminal Domain (BET) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, BET inhibitors currently exhibit a proliferating pipeline with 30+ therapeutic candidates.

BET Inhibitors Pipeline Insights

BET proteins are epigenetic readers characterized by the presence of two tandem bromodomains (BD1 and BD2), extraterminal domain (ET), and a C-terminal domain (CTD). Moreover, these proteins also recognize acetylated nonhistone proteins, including different transcription factors.

The BET proteins play a vital role in transcription as they bind with chromatin. Due to their involvement in transcription, the BET proteins have been targeted by various therapeutic agents in the field of cancer. The BET inhibitors refer to those molecules that bind to the MYC gene by attaching to acetylated lysine motifs and prevent the interaction between acetylated lysine and BET proteins. This blockade of the gene expressions terminates the transcription and results in the death of tumor cells.

Insights into Pipeline Segments

According to the research, drugs being developed for BET inhibitors, most of which are in clinical phases, can be administered through oral route. It has been found that the oral route of medication is convenient, economical, and non-invasive. It has an additional advantage wherein it can be easily modified for rapid or extended release more efficiently as compared to other routes of administration.

Positive Clinical Trial Results Play a Pivotal Role in BET Inhibitors Pipeline Advancements

There are several companies that are involved in developing therapeutics targeting BET proteins have shown positive clinical results in various phases of drug development. For instance, in December 2018, Resverlogix Corp. announced positive data of the Phase III trial, evaluating apabetalone (RVX-208), a first-in-class, small molecule that is selective BET inhibitor for the treatment of patients with high-risk cardiovascular disease with type 2 diabetes mellitus and low levels of high-density lipoprotein. The results of the study concluded that the drug was well tolerated and no safety issues were encountered.

Designation Grants by Regulatory Bodies to Accelerate the Development Process of BET Inhibitors

Companies are actively seeking designation grants to accelerate the process of development. For instance, in November 2018, Constellation Pharmaceuticals Inc. received Fast Track Designation from the United States Food and Drug Administration (USFDA) for CPI-0610 for the treatment of myelofibrosis (MF), based on preliminary results from the company’s Phase II study, MANIFEST.

Browse Detailed Report at:

Constellation Pharmaceuticals Inc., Resverlogix Corp., GlaxoSmithKline plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Co. Ltd., and FORMA Therapeutics Inc. are some of the key players developing BET inhibitors.

BET Inhibitors Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of BET inhibitors under development. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of BET inhibitors. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to BET inhibitors.